President Trump’s spending plan — running into opposition from Republicans and Democrats alike — would cut about 20 percent of the roughly $30 billion budget of the U.S. medical research agency.
Two of the women mistakenly thought they were participating in a clinical trial, as the procedure was advertised on a government-run clinical trial website.
Scott Gottlieb, nominated to lead the U.S. Food and Drug Administration has deep ties to industry, and has worn many other hats in his career.
Telehealth services may boost access to care, but they don’t save money, according to a new study.
Building on weeks of mounting pressure to address high prescription drug prices, three influential U.S. senators have asked the government’s accountability arm to probe the orphan drug program for potential misuse.
At least 83 percent of the United States’ largest patient advocacy groups take contributions from the drug industry, and not all of them are transparent about it.
The U.S. medical system depends on doctors from other countries, who often work in areas in desperate need of providers.
Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration’s plans to speed up drug approvals and dramatically reduce regulations at the agency.
The new Health and Human Services secretary could quickly change the course of health policy in the United States, affecting everything from women’s healthcare to tobacco regulation.
U.S. Health and Human Services secretary nominee Tom Price showed little restraint in his personal stock trading, despite the fact that a House committee he was on was under investigation.